Vikas Lifecare Q3 FY26 loss, warrants plan in 2026

What Vikas Lifecare disclosed

Vikas Lifecare Limited published newspaper advertisements of its Q3 FY26 unaudited financial results in Financial Express and Jansatta on April 24-25, 2026. The disclosures covered results for the quarter ended December 31, 2025, and were stated to be in line with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company reported that the results had been approved by its Board of Directors, after review by the Audit Committee. It also stated that the statutory auditor carried out a limited review.

The advertisements highlighted that performance looked mixed across quarters, with losses reported for the December 2025 quarter. Alongside these quarterly numbers, the company also disclosed total income for the nine months ended December 31, 2025 on both consolidated and standalone bases. The disclosures were digitally signed by Managing Director Sundeep Kumar Dhawan (DIN: 09508137), as per the information shared.

Board approval and the timeline of filings

According to the information provided, the Board meeting that approved the unaudited financial results was held on April 21, 2026. The approvals covered standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2025, and for the quarter and nine months ended December 31, 2025. The company stated the results were reviewed by the Audit Committee and subjected to limited review by the statutory auditors.

Separate updates in the text also referenced a board meeting originally scheduled for February 7, 2026 that was postponed due to technical reasons, where unaudited financial results for the quarter and half year ended September 30, 2025 were to be considered. A trading window closure was also referenced as being in place since October 1, 2025, tied to pending finalisation and disclosure of unaudited Q2 FY2026 results, with reopening stated as 48 hours after the results are disclosed.

Q3 FY26: net loss on both bases

For the quarter ended December 31, 2025, the newspaper advertisement stated a consolidated net loss of ₹2,927.64 lakhs and a standalone net loss of ₹1,472.41 lakhs. Converted to a single base unit, these losses are ₹29.2764 crore (consolidated) and ₹14.7241 crore (standalone).

The company also shared, in the provided text, that ratios were based on the latest audited financial result. Separately, it was noted that the company had negative cash flow from operations of -232.8501 (unit not specified in the provided extract).

Nine-month FY26 income figures (up to December 2025)

For the nine months ended December 31, 2025, the company reported total income of ₹46,560.00 lakhs on a consolidated basis and ₹45,949.12 lakhs on a standalone basis. In crore terms, this equals ₹465.6 crore (consolidated) and ₹459.4912 crore (standalone).

These figures provide context for the scale of operations through the first nine months of the financial year, even as the December quarter was reported as loss-making. The disclosure did not provide additional segment-level detail in the provided extract.

Quarterly operating trend: net sales and EPS

The extract included a quarterly table (all figures in crore) showing net sales across five quarters, from December 2024 to December 2025, along with adjusted EPS.

In this sequence, net sales peaked at ₹140.98 crore in September 2025 and then declined to ₹96.54 crore in December 2025. Adjusted EPS in the table was negative in four out of the five quarters shown, with the weakest value of -0.08 in December 2025.

FY2025 audited context from the annual narrative

The provided text also included a performance summary for the year ended March 31, 2025. On a consolidated basis, revenue from operations increased from ₹471.9023 crore (₹47,190.23 lakhs) to ₹505.9852 crore (₹50,598.52 lakhs). It also stated that the company reported a loss of ₹10.9156 crore (₹1,091.56 lakhs) for the year under review, compared with a profit of ₹13.4540 crore (₹1,345.40 lakhs) in the previous year.

On a standalone basis, the company stated it achieved turnover of ₹489.9027 crore (₹48,990.27 lakhs) versus ₹442.8888 crore (₹44,288.88 lakhs) in the previous year. It reported a loss of ₹2.2566 crore (₹225.66 lakhs) during the year, compared with a profit of ₹19.3242 crore (₹1,932.42 lakhs) in the previous year.

Capital actions: postal ballot for warrants and other approvals

The extract stated that the company issued a postal ballot notice seeking shareholder approval through remote e-voting for three key resolutions. One resolution involved issuance of 61,90,62,500 convertible warrants worth Rs. 99,05,00,000 (₹99.05 crore) to promoters and public investors. The other resolutions mentioned included alteration of Articles of Association for future capital issuance and an increase in authorised share capital from Rs. 235 crores to an amount that was not fully visible in the provided text.

The board also approved seeking members’ consent through an addendum to the postal ballot notice for undertaking various transactions, including related party transactions, investments, loans, guarantees, and creation of charges or mortgages, within limits approved by members, to facilitate business operations.

Key facts at a glance

Market impact: what investors typically track in such updates

From the information provided, the immediate market relevance lies in the combination of (1) reported losses for the December 2025 quarter, (2) the timing of delayed disclosures and trading window restrictions cited in the extract, and (3) the proposed capital raising via convertible warrants. Investors also tend to track limited review status for unaudited numbers, which the company stated it received from its statutory auditor.

The quarterly net sales pattern shown in the table indicates volatility across FY25 and FY26 quarters presented, while adjusted EPS remained negative in most quarters. Separately, the FY2025 narrative provided a year-level view of revenue growth, alongside a shift to loss at both consolidated and standalone levels.

Analysis: why the combination of results and capital items matters

The disclosures place operating performance and capital planning in the same news cycle. The Q3 FY26 net losses (December 2025 quarter) are significant in absolute terms, and are accompanied by nine-month total income figures that help frame scale. At the same time, the postal ballot resolutions point to potential dilution-linked instruments via convertible warrants and governance steps related to future capital issuance.

The extract also referenced trading window closures tied to pending results, which is closely watched in listed companies because it shapes how and when insiders can trade. Finally, the mention of negative cash flow from operations suggests investors may focus on whether reported income translates into operating cash generation, although the unit for the cited cash flow figure was not provided in the text.

Conclusion

Vikas Lifecare’s April 2026 disclosures combined Q3 FY26 loss reporting, nine-month income figures up to December 2025, and steps toward shareholder approvals for convertible warrants and other permissions through a postal ballot process. The next milestones, based on the provided extract, are shareholder voting outcomes on the postal ballot resolutions and subsequent exchange updates tied to the approved unaudited results and related compliance filings.